Literature DB >> 16721383

Inflammation and multiple myeloma: the Toll connection.

A Mantovani, C Garlanda.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721383     DOI: 10.1038/sj.leu.2404229

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

Review 1.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

Review 2.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

3.  Multiple myeloma precursor disease.

Authors:  Ola Landgren; Adam Justin Waxman
Journal:  JAMA       Date:  2010-12-01       Impact factor: 56.272

Review 4.  Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Authors:  Adam J Waxman; Michael Kuehl; Arun Balakumaran; Brendan Weiss; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-08

Review 5.  The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

Authors:  Jeff J Subleski; Qun Jiang; Jonathan M Weiss; Robert H Wiltrout
Journal:  Immunotherapy       Date:  2011-10       Impact factor: 4.196

6.  Toll-like Receptors in Chronic Lymphocytic Leukemia.

Authors:  Marta Muzio; Eleonora Fonte; Federico Caligaris-Cappio
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-08-09       Impact factor: 2.576

7.  Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption.

Authors:  Phoebe K Mondala; Ashni A Vora; Tianyuan Zhou; Elisa Lazzari; Luisa Ladel; Xiaolin Luo; Youngsoo Kim; Caitlin Costello; A Robert MacLeod; Catriona H M Jamieson; Leslie A Crews
Journal:  Cell Stem Cell       Date:  2021-01-20       Impact factor: 24.633

8.  Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells.

Authors:  J Abdi; T Mutis; J Garssen; F Redegeld
Journal:  Blood Cancer J       Date:  2013-05-31       Impact factor: 11.037

9.  Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma.

Authors:  Hyewon Lee; Sun-Young Kong; Ji Yeon Sohn; Hyoeun Shim; Hye Sun Youn; Sangeun Lee; Hyun Ju Kim; Hyeon-Seok Eom
Journal:  Biomed Res Int       Date:  2014-05-21       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.